GlassScriptPhysician profile
Victor Padilla
NPI 1518955020
$2,499.13
in general payments reported to CMS, 2019-2025
22 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $449 · 2021: $551 · 2022: $261 · 2023: $277 · 2024: $236 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $664.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $795.99 | 2019-2024 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $421.79 | 2019-2023 | Ocaliva |
| Redhill Biopharma INC. | $246.61 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Takeda Pharmaceuticals U.S.A., INC. | $183.73 | 2019-2022 | |
| Madrigal Pharmaceuticals | $132.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $107.58 | 2022-2025 | Ibsrela |
| Medtronic, INC. | $100.53 | 2022-2024 | Gi Genius |
| Abbvie INC. | $92.74 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $67.89 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $60.06 | 2019-2024 | Sutab |
| Qol Medical, LLC | $41.19 | 2020-2021 | |
| Janssen Biotech, INC. | $34.53 | 2021-2023 | Stelara |
| Ferring Pharmaceuticals INC. | $29.37 | 2019 | |
| Romark Laboratories, Lc | $25.02 | 2019 | |
| Celgene Corporation | $23.95 | 2023 | Zeposia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.70 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $23.49 | 2024 | |
| Shire North American Group INC | $21.76 | 2019 | |
| Alfasigma USA, INC. | $20.74 | 2021 | |
| Nestle Healthcare Nutrition INC. | $19.92 | 2021 | |
| Allergan, INC. | $12.91 | 2020 | |
| Vivus LLC | $12.72 | 2023 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Padilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.